•  
  •  
  •  
  •  

2023-02-04 08:58:59

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Ador Welding Ltd reports consolidated Q3FY23 PAT of Rs. 16.36 crores
  • Heubach Colorants India Ltd Q3 FY2023 profit at Rs. 6.72 crores
  • Foods and Inns Ltd posts consolidated profit of Rs. 11.25 crores in Q3 FY2022-23
  • Nureca Ltd Q3 FY2023 consolidated net profit at Rs. 30.1 lakhs
  • Shree Rajasthan Syntex Ltd Q3FY23 loss at Rs. 7.57 crores

Keywords Selected:  RDY

Research

  • Dr. Reddy's Laboratories - Analyst Meet Update - Multiple growth initiatives - BUY

Stock Report

  • Hindustan Hardy Ltd Q3 FY23 net profit soars to Rs. 1.58 crore
  • Dr. Reddys Laboratories Ltd Q3 FY2023 consolidated PAT climbs to Rs. 1243.9 crores
  • Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
  • Dr. Reddy's launches in-house palbociclib to widen access to high-quality breast cancer drug
  • Dr. Reddy's successfully completes Phase 1 study of DRL_TC, a proposed biosimilar of tocilizumab
  • Dr. Reddy's Research and Development BV to sell certain assets at Leiden, The Netherlands
  • Aurigene reports results of AUR101 in Phase II Study in Patients with moderate to severe psoriasis
  • Dr. Reddy's Laboratories Ltd updates on antitrust litigation
  • Dr Reddys Laboratories Ltd Q2FY23 consolidated profit at Rs. 1112.8 crores
  • World Economic Forum recognises Dr. Reddy's Hyderabad factory as part of its Global Lighthouse Network
  • LIC increases stake in Dr Reddys Laboratories Ltd
  • Dr. Reddy's Laboratories launches Lenalidomide Capsules in the U.S.
  • Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma
  • Dr Reddys Laboratories Ltd consolidated Q1FY2023 net profit surges to Rs. 1187.6 crores
  • Dr. Reddy's Laboratories launches Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
  • Dr. Reddy's announces the first-to-market launch of over-the-counter, store-brand equivalent of Allegra-D® 24 HR in the U.S. Market
  • Dr. Reddy's Laboratories updates on PAI of formulations facility
  • Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior Inc
  • Dr. Reddy's Laboratories announces the acquisition of an injectable product portfolio from Eton Pharma
  • Dr. Reddy's Laboratories announces launch of the generic version of Nexavar in the U.S. market
  • Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies
  • Torrent Pharma acquires 4 Brands from Dr. Reddy's Laboratories
  • Hindustan Hardy Ltd reports Rs. 59.78 lakhs PAT in Q4FY22
  • Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announces the launch Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market

Latest Post

  • Ador Welding Ltd reports consolidated Q3FY23 PAT of Rs. 16.36 crores
  • Heubach Colorants India Ltd Q3 FY2023 profit at Rs. 6.72 crores
  • Foods and Inns Ltd posts consolidated profit of Rs. 11.25 crores in Q3 FY2022-23
  • Nureca Ltd Q3 FY2023 consolidated net profit at Rs. 30.1 lakhs
  • Shree Rajasthan Syntex Ltd Q3FY23 loss at Rs. 7.57 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
No:AP-172, 2nd Sector, 10th Street, KK Nagar
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

Disclaimer Copyright © - 2022